This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rieckmann, P. Articles by Oger, J. Search for Related Content Social Bookmarking                   What's this?

Review: Escalating immunotherapy of multiple sclerosis

Multiple Sclerosis Program Division of Neurology, University of British Columbia, Vancouver, Canada prieckmann{at}brain.ubc.ca

Anthony Traboulsee

Virginia Devonshire

Multiple Sclerosis Program, Division of Neurology, University of British Columbia, Vancouver, Canada

Joel Oger

Multiple Sclerosis Program, Division of Neurology, University of British Columbia, Vancouver, Canada

Basic disease-modifying treatment for relapsing forms of active multiple sclerosis (MS) is now available in many countries with high prevalence rates, for this chronic inflammatory disease of the central nervous system. Several lines of evidence support early immunomodulatory treatment with either recombinant interferon-beta or glatiramer acetate, and positive results from phase III trials encourage start of treatment even in patients with clinically isolated syndromes (CIS). However, currently available drugs for basic therapy are only partially effective and patients may still encounter relapses or disease progression. As treatment-refractory, clinically active MS can quickly lead to irreversible neurological disability there is an urgent need for effective escalating strategies. Patients with suboptimal treatment response to basic therapy have been treated with combination therapies, cytotoxic drugs (such as mitoxantrone and cyclophosphamide) or autologous hematopoietic stem cell transplantation. Recently, the monoclonal antibody, natalizumab, was added to this armamentarium. None of these strategies have been vigorously evaluated in large randomized, controlled phase III trials with patients who failed basic therapy. Therefore, the decision to escalate immunotherapy is still based on limited evidence. This article will review potential candidates for intensified immunosuppression and call for innovative study designs to better evaluate escalating immunotherapy in MS.

Key Words: immunotherapy • natalizumab • interferon-beta • glatiramer acetate • multiple sclerosis • clinically isolated syndromes

Therapeutic Advances in Neurological Disorders, Vol. 1, No. 3, 181-192 (2008)
DOI: 10.1177/1756285608098359


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?